“Insanity is doing the same things over and over but expecting different results,” Rita Mae Brown. Most of us would agree. And yet, year after year, we invest over $90 billion in R&D, only to face a staggering 96% failure rate. Isn’t it time we break out of this loop? Does the path to market for new cancer drugs have to remain a “valley of death,” or can we engineer a molecule-to-medicine expressway with emerging technologies? This panel, led by industry trailblazers, will unlock synergies in cutting-edge AI/ML, personalized medicine, and indispensable collaborations for bridging the valley of death with a Molecule-to-Medicine Expressway. Together, speakers and attendees will bring to light actionable strategies, avenues in making these accessible even to smaller biopharma companies, and the imperative for coming together to accelerate breakthroughs and blockbusters in oncology. Attendees will gain insights into new approaches that can help bridge the gap from discovery to deals, reduce risk, and accelerate the journey from drug discovery to successful partnerships and licensing.